Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy

Blood

Volumn 113, Issue 4, 2009, Pages 797-806

  Niemeyer, Glenn P ^a,b   Herzog, Roland W ^c   Mount, Jane ^a   Arruda, Valder R ^d   Tillson, D Michael ^a   Hathcock, John ^a   Van Ginkel, Frederik W ^a   High, Katherine A ^d   Lothrop Jr, Clinton D ^a,b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BILE ACID; BLOOD CLOTTING FACTOR 9; MESSENGER RNA; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING TIME; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; EMBRYO; EXTRACHROMOSOMAL INHERITANCE; GENE AMPLIFICATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; HEMOPHILIA B; HUMAN; HUMAN CELL; LIVER; LIVER BIOPSY; MALE; MUSCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT DURATION; ADENO ASSOCIATED VIRUS; ANIMAL; DOG; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; TIME;

ANIMALS; DEPENDOVIRUS; DNA, VIRAL; DOGS; FACTOR IX; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA B; IMMUNE TOLERANCE; LIVER; RNA, MESSENGER; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 59649122961     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-181479     Document Type: Article

References (45)

1. Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost. 2004;30:205-213.
2. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno- associated viral vector. Nat Med. 1999;5:56-63.
3. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4:192-200.
4. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99:2670-2676.
5. High KA. Gene transfer as an approach to treating hemophilia. Semin Thromb Hemost. 2003;29: 107-120.
6. Lillicrap D, VandenDriessche T, High K. Cellular and genetic therapies for haemophilia. Haemophilia. 2006;12(Suppl 3):36-41.
7. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261.
8. Manno CS, Chew AJ, Hutchison S, et al. AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963-2972.
9. Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006;14:452-455.
10. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342-347.
11. Mingozzi F, Maus MV, Hui DJ, et al. CD8(-) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13:419-422.
12. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2004;103:85-92.
13. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by musclegene transfer is limited by a local immune response. Blood. 2005;105:4226-4234.
14. Wang L, Herzog RW. AAV-mediated gene transfer for treatment of hemophilia. Curr Gene Ther. 2005;5:349-360.
15. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, Herzog RW. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A. 2006;103:4592-4597.
16. Dobrzynski E, Mingozzi F, Liu YL, et al. Induction of antigen-specific CD4-T-cell anergy and deletion by in vivo viral gene transfer. Blood. 2004; 104:969-977.
17. Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood. 2003;101:3924-3932.
18. Wang B, O'Malley TM, Xu L, et al. Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab. 2006;87:8-21.
19. Xu L, Nichols TC, Sarkar R, McCorquodale S, Bellinger DA, Ponder KP. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A. 2005;102:6080-6085.
20. Gao C, Sands MS, Haskins ME, Ponder KP. Delivery of a retroviral vector expressing human --glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther. 2000;2:233-244.
21. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006;108:107-115.
22. Xu L, Haskins ME, Melniczek JR, et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of --glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther. 2002;5:141-153.
23. Xu L, Mango RL, Sands MS, Haskins ME, Ellinwood NM, Ponder KP. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther. 2002;6:745-758.
24. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature. 2006;440:1123.
25. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 2001; 8:1343-1346.
26. Herzog RW, Cao O, Hagstrom JN, Wang L. Gene therapy for treatment of inherited haematological disorders. Expert Opin Biol Ther. 2006;6:509-522.
27. Le M, Okuyama T, Cai SR, et al. Therapeutic levels of functional human factor X in rats after retroviral- mediated hepatic gene therapy. Blood. 1997; 89:1254-1259.
28. Mauser AE, Whitlark J, Whitney KM, Lothrop CD, Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood. 1996;88:3451-3455.
29. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003;111:1347-1356.
30. Center SA, Baldwin BH, Erb HN, Tennant BC. Bile acid concentrations in the diagnosis of hepatobiliary disease in the dog. J Am Vet Med Assoc. 1985;187:935-940.
31. Center SA, ManWarren T, Slater MR, Wilentz E. Evaluation of twelve-hour preprandial and twohour postprandial serum bile acids concentrations for diagnosis of hepatobiliary disease in dogs. J Am Vet Med Assoc. 1991;199:217-226.
32. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAVmediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4:201-210.
33. Hausl C, Maier E, Schwarz HP, et al. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost. 2002;87:840-845.
34. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther. 2005;12: 1453-1464.
35. Dobrzynski E, Herzog RW. Tolerance induction by viral in vivo gene transfer. Clin Med Res. 2005;3: 234-240.
36. Cao O, Dobrzynski E, Wang L, et al. Induction and role of regulatory CD4-CD25-T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood. 2007;110:1132-1140.
37. Cao O, Furlan-Freguia C, Arruda VR, Herzog RW. Emerging role of regulatory T cells in gene transfer. Curr Gene Ther. 2007;7:381-390.
38. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-276.
39. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol. 1999; 73:5438-5447.
40. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003;34:297-302.
41. Nakai H, Wu X, Fuess S, et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol. 2005;79: 3606-3614.
42. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adenoassociated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75:6969-6976.
43. Schmidt M, Carbonaro DA, Speckmann C, et al. Clonality analysis after retroviral-mediated gene transfer to CD34-cells from the cord blood of ADA-deficient SCID neonates. Nat Med. 2003;9: 463-468.
44. Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther. 2006;14:34-44.
45. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317:477.